15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Anixa Biosciences Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $7.00 to $10.00, a moderate spread. The average target of $8.50 sits 146% above the current $3.46. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.08 next quarter toward $-0.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Anixa Biosciences Inc.
As of Jul, 2 of 2 firms rate ANIX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ANIX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 1 analysts · -11% YoY
Next period, 1 analysts expect Anixa Biosciences Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus $-0.09 a year earlier. Full-year consensus is $-0.31, growing to $-0.31 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Anixa Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANIX.
#1
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$7.00+102.3% to target
Overall win rate
34%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$10.00+189.0% to target
Overall win rate
22%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #360
Buy
$10.00+189.0% to target
Overall win rate
30%
+ Follow
#4
Jason Kolbert
EF Hutton
Buy
$10.00+189.0% to target
Coverage
—
+ Follow
ANIX stock forecast FAQ
What is ANIX's average 12-month price target?+
The 2 analysts with a live target average $8.50 for Anixa Biosciences Inc over the next 12 months, ranging from a $10.00 high to a $7.00 low.
Is ANIX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ANIX?+
The Street-high target is $10.00 (D. Boral Capital), and the Street-low is $7.00 (HC Wainwright & Co.). The average of all 2 active targets is $8.50.
How many Wall Street analysts cover ANIX?+
2 analysts have an active rating on Anixa Biosciences Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ANIX?+
Among analysts who currently cover ANIX, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #238). Their current call is Buy with a $7.00 target.
What is Anixa Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 1 analysts. Full-year EPS is projected at $-0.31, rising to $-0.31 the following year.
How much revenue is Anixa Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ANIX lately?+
As of Jul, 2 of 2 firms rate ANIX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANIX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
